Beese Fulmer Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.48M Buy
40,897
+5,075
+14% +$296K 0.16% 98
2025
Q4
$1.93M Buy
35,822
+12,198
+52% +$587K 0.13% 108
2025
Q3
$1.07M Sell
23,624
-828
-3% -$38.7K 0.07% 139
2025
Q2
$1.13M Sell
24,452
-564
-2% -$27.7K 0.08% 134
2025
Q1
$1.53M Sell
25,016
-193
-0.8% -$11.3K 0.13% 103
2024
Q4
$1.43M Buy
25,209
+18
+0.1% +$1.01K 0.12% 103
2024
Q3
$1.3M Sell
25,191
-724
-3% -$34K 0.11% 109
2024
Q2
$1.08M Sell
25,915
-1,288
-5% -$57.6K 0.1% 115
2024
Q1
$1.48M Sell
27,203
-2,902
-10% -$148K 0.14% 101
2023
Q4
$1.54M Sell
30,105
-4,047
-12% -$212K 0.16% 96
2023
Q3
$1.98M Sell
34,152
-1,964
-5% -$120K 0.22% 83
2023
Q2
$2.31M Sell
36,116
-3,571
-9% -$239K 0.25% 78
2023
Q1
$2.75M Sell
39,687
-846
-2% -$59.7K 0.31% 73
2022
Q4
$2.92M Buy
40,533
+1
+0% +$75 0.35% 73
2022
Q3
$2.88M Sell
40,532
-1,499
-4% -$109K 0.39% 70
2022
Q2
$3.24M Buy
42,031
+778
+2% +$59.3K 0.41% 65
2022
Q1
$3.01M Sell
41,253
-2,356
-5% -$158K 0.33% 75
2021
Q4
$2.72M Sell
43,609
-3,183
-7% -$187K 0.28% 82
2021
Q3
$2.77M Sell
46,792
-58
-0.1% -$3.82K 0.31% 81
2021
Q2
$3.13M Sell
46,850
-1,430
-3% -$93.2K 0.35% 79
2021
Q1
$3.05M Sell
48,280
-2,971
-6% -$185K 0.37% 77
2020
Q4
$3.18M Sell
51,251
-1,811
-3% -$111K 0.41% 68
2020
Q3
$3.2M Sell
53,062
-2,215
-4% -$133K 0.45% 62
2020
Q2
$3.25M Sell
55,277
-3,287
-6% -$197K 0.48% 63
2020
Q1
$3.26M Sell
58,564
-2,356
-4% -$144K 0.58% 60
2019
Q4
$3.91M Buy
60,920
+2,543
+4% +$146K 0.55% 63
2019
Q3
$2.96M Buy
58,377
+10,644
+22% +$500K 0.44% 71
2019
Q2
$2.17M Sell
47,733
-1,145
-2% -$53.3K 0.41% 69
2019
Q1
$2.33M Sell
48,878
-1,653
-3% -$82.3K 0.46% 66
2018
Q4
$2.63M Sell
50,531
-1,448
-3% -$77.8K 0.59% 58
2018
Q3
$3.23M Sell
51,979
-4,581
-8% -$272K 0.63% 58
2018
Q2
$3.13M Sell
56,560
-6,042
-10% -$326K 0.66% 59
2018
Q1
$3.96M Buy
62,602
+1,284
+2% +$82.6K 0.87% 50
2017
Q4
$3.76M Buy
61,318
+953
+2% +$59.6K 0.81% 50
2017
Q3
$3.85M Buy
60,365
+2,193
+4% +$128K 0.88% 48
2017
Q2
$3.24M Buy
58,172
+1,507
+3% +$82K 0.77% 52
2017
Q1
$3.08M Buy
56,665
+3,528
+7% +$194K 0.75% 54
2016
Q4
$3.1M Buy
53,137
+1,024
+2% +$56K 0.8% 50
2016
Q3
$2.81M Buy
52,113
+4,278
+9% +$275K 0.76% 52
2016
Q2
$3.52M Buy
47,835
+8
+0% +$565 1% 43
2016
Q1
$3.16M Buy
47,827
+2,714
+6% +$171K 0.92% 47
2015
Q4
$3.1M Buy
45,113
+6,322
+16% +$418K 0.96% 44
2015
Q3
$2.3M Buy
38,791
+3,413
+10% +$217K 0.75% 48
2015
Q2
$2.35M Buy
35,378
+200
+0.6% +$13.2K 0.76% 51
2015
Q1
$2.27M Sell
35,178
-517
-1% -$32.4K 0.76% 48
2014
Q4
$2.11M Buy
35,695
+805
+2% +$45.4K 0.66% 54
2014
Q3
$1.79M Buy
34,890
+372
+1% +$18.6K 0.58% 55
2014
Q2
$1.67M Buy
34,518
+2,315
+7% +$114K 0.54% 57
2014
Q1
$1.67M Buy
32,203
+1,793
+6% +$95.4K 0.58% 55
2013
Q4
$1.62M Buy
30,410
+2,242
+8% +$114K 0.57% 55
2013
Q3
$1.3M Buy
28,168
+2,419
+9% +$106K 0.51% 58
2013
Q2
$1.15M Buy
+25,749
New +$1.12M 0.49% 59

Other funds holding BMY

Beese Fulmer Investment Management's BMY Position: Q1 2026 in Review

Beese Fulmer Investment Management increased its Bristol-Myers Squibb (BMY) stake by 14% in Q1 2026, buying an estimated $296K and bringing the position to 40,897 shares worth $2.48M. The position accounts for 0.16% of the portfolio, ranked #98.

Beese Fulmer Investment Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.96M in Q1 2018. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Beese Fulmer Investment Management held 40,897 shares of Bristol-Myers Squibb worth $2.48M as of Q1 2026.
  • Beese Fulmer Investment Management bought 5,075 Bristol-Myers Squibb shares in Q1 2026, an estimated $296K.
  • Bristol-Myers Squibb made up 0.16% of Beese Fulmer Investment Management's portfolio in Q1 2026, its #98 holding.
  • Beese Fulmer Investment Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Beese Fulmer Investment Management's Bristol-Myers Squibb position peaked at $3.96M in Q1 2018.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Beese Fulmer Investment Management's 13F filing for Q1 2026, filed 16 Apr 2026.